Skip to main content

Life Sciences is now live. See how →

Patent Examiner Noble E. Jarrell

Art Unit 1699 · Drug Compounds, Formulations, Agrochemicals & Microorganisms · Tech Center 1600 · 280 applications filed 2021–2026

⚑ Hard · harder than 70% of examiners● Free examiner data

Noble E. Jarrell is a USPTO patent examiner in Art Unit 1699 (Drug Compounds, Formulations, Agrochemicals & Microorganisms) with 280 applications from filing years 2021–2026. Examiner Jarrell's allowance rate is 72.7%, below the 82.2% USPTO average for applications filed in the same years. The examiner ranks harder than 70% of examiners. In 2021, decided applications with an examiner interview were allowed 28.2 percentage points more often than those without.

Data through November 2026 from USPTO Patent Center (formerly PAIR) · Methodology

Overview

Free
Difficulty · Hard
harder than 70% of examiners
Easier70th percentileHarder
Allowance rate vs peers
Examiner Jarrell72.7%
Art Unit 169967.6%
USPTO average82.2%
Allowance rate
72.7%
▼ USPTO avg 82.2%
Applications
280
filing years 2021–2026
First-action allowance
11.0%
patented with no rejection
Abandoned
15.0%
share of applications
Avg office actions
1.0
USPTO avg 1.3
Days to first OA
935
▲ USPTO 623
RCE rate
10.4%
USPTO 19.2%
Interview rate
15.4%
USPTO 26.8%

Examiner details

  • Art unit1699 · Drug Compounds, Formulations, Agrochemicals & Microorganisms
  • Title / gradePrimary Patent Examiner · GS-14
  • Service23 years
  • PhoneOn each office action
  • Email[email protected]
  • In USPTO recordsJARRELL, NOBLE E
Full signatory authority

Examiner Jarrell can allow an application without a supervisory sign-off.

Examines (USPC classes)
514 · Drug, Bio-Affecting & Body Treating Compositions544 · Organic Compounds (Class 532-570 Series)540 · Organic Compounds (Class 532-570 Series)

How to improve your odds with Examiner Jarrell

  • The data favors an interview. Interviewed cases were allowed more often in all 3 measured years, by 28.2 to 40.6 points.
  • Plan for the timeline. First office action averages 935 days vs the 623-day USPTO norm.
  • Expect a §112. Definiteness & disclosure is the most-issued rejection (109), and applicants overcame it 78.8% of the time.
  • The data favors an RCE here. Cases with an RCE were allowed more often in both measured years, by 25.9 to 31.9 points.

Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.

Rejection patterns & how they get overcome

Free
§102 Novelty64 issued · 77.1% overcome
§103 Obviousness32 issued · 85.0% overcome
§112 Definiteness & disclosure109 issued · 78.8% overcome
How applicants traverse §112 rejections🔒 Members

Applicants overcame 52 of the 66 decided §112 definiteness & disclosure rejections from Examiner Jarrell in the data. Each winning response, with its arguments and claim amendments, is in the file wrapper.

Read the winning §112 argumentsFull REMARKS, amendments, claim trees & redlines from the file wrappers
Start free

Just got an office action from Examiner Jarrell?

Draft your response with Examiner Jarrell's record and Art Unit 1699's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See the office action response tools in AI Studio.

Open AI Studio free →

RCE behavior

Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Jarrell.

YearRCE rateAllowance w/ RCEAllowance w/oDelta
202217.7%100.0%74.1%+25.9pp
202117.2%100.0%68.1%+31.9pp

Recent outcomes

Free🔒 Case detail for members
App #TitleOutcomeOAsArguments & redline
18/598629Aurora Kinase Inhibitors for Inhibiting Mitotic ProgressionPatented0🔒 View
18/516585Crystalline Polymorphs of a Muscarinic Acetylcholine Receptor AgonistPatented1🔒 View
18/273956Administration Method of a Chemotherapeutic AgentPatented1🔒 View
19/388266Ras InhibitorsPatented1🔒 View
See all 280 applications with full file-wrapper detailOffice action text, attorney arguments, amendments & claim-by-claim track changes
Start free

Art Unit 1699 technology

Small-molecule drug compoundsCosmetic & drug formulationsPesticides & plant growth regulatorsMicrobial, enzyme & cell compositionsTop CPC A61K · C07D · C12N
About this examiner. Noble E. Jarrell examines in Art Unit 1699 (Drug Compounds, Formulations, Agrochemicals & Microorganisms, Tech Center 1600). Working on compound or antibody claims? See Life Sciences in AI Studio.

Frequently asked questions

What is Examiner Noble E. Jarrell's allowance rate?
Examiner Jarrell's allowance rate is 72.7%, compared with 82.2% across the USPTO and 67.6% in Art Unit 1699 for applications filed in the same years. That rate ranks Examiner Jarrell harder than 70% of examiners.
Is Examiner Jarrell a hard examiner?
Somewhat. Examiner Jarrell ranks harder than 70% of examiners, in the 70th difficulty percentile (hard). Examiner Jarrell has a 72.7% allowance rate versus 82.2% across the USPTO and 67.6% in Art Unit 1699, 1.0 office actions per application versus 1.3, and an RCE rate of 10.4% versus 19.2% across the USPTO, for applications filed in the same years.
Do examiner interviews help with Examiner Jarrell?
In this examiner's record, yes. Decided applications with an interview were allowed more often in each of the 3 measured years, by 28.2 to 40.6 percentage points. In 2021, 92.3% of decided applications with an interview were allowed, versus 64.1% of those without.
What is Examiner Jarrell's most common rejection?
§112 definiteness & disclosure, issued 109 times in the data. Applicants overcame it 78.8% of the time.
Is an RCE worth filing with Examiner Jarrell?
In this examiner's record, yes. Decided applications with an RCE were allowed more often in both measured years, by 25.9 to 31.9 percentage points. In 2022, 100.0% of decided applications with an RCE were allowed, versus 74.1% of those without one.
How long until the first office action from Examiner Jarrell?
About 935 days on average, versus 623 days across the USPTO for applications filed in the same years.
How do I contact Examiner Noble E. Jarrell?
Examiner Jarrell can be reached by email at [email protected]. The examiner's direct line is listed at the end of the examiner's office actions.

Put Examiner Jarrell's data to work on your next response.

Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.

Start free
Statistics are computed by Boundly Prosecution Intel from USPTO Patent Center (formerly PAIR) file wrappers for filing years 2021–2026, refreshed regularly. Allowance rate (sometimes called grant rate) is the share of disposed applications that issued as patents. Office actions here are non-final and final rejections, so restriction requirements and allowances are not counted. USPTO benchmarks are weighted to each examiner's mix of filing years, and art-unit benchmarks to the art units and filing years of the examiner's own applications, so they compare like for like. The difficulty percentile ranks examiners, each counted once, so it can point the other way from the USPTO average, which counts applications. See how each number is computed. The year-by-year interview and RCE tables show up to four recent filing years, leaving out the newest one and any year with fewer than ten applications or five decided applications on either side. Historical data is provided for informational purposes only. Past examiner behavior does not guarantee future outcomes, and nothing here is legal advice or a substitute for advice from a licensed patent attorney or agent. Are you Noble E. Jarrell, or see an error? Request a correction.